Bronchoalveolar Lavage Fluid α Amylase Level a Promising Biomarker of Aspiration Syndrome: A Pilot Study.

Authors

Hui Xu, Kun Wang, Yeliang Wen, Ruixue Zhang, Fei Tang, Yan Hu, Hui Geng, Xin Cong, Lianjun Lin, Shiyue Li

Published in

Infection and drug resistance. Volume 19. Pages 610026. Epub Aug 10, 2026.

Abstract

Aspiration syndrome is a common respiratory disease in clinical practice. We hypothesized that bronchoalveolar lavage fluid (BALF) α-amylase might be a diagnostic biomarker for aspiration syndrome.
This pilot, multicenter prospective study reviewed consenting adults who underwent clinically-indicated bronchoscopy at six hospitals. BALF samples were obtained using standardized methods. Amylase levels were measured in clinical biochemical laboratory. Aspiration syndrome was clinically diagnosed based on the Expert Task Force on Diagnosis And Treatment of Aspiration Pneumonia in Adults in China (2022) and the guidelines of the Japanese Respiratory Society.
Among 248 participants, 159 met clinical criteria for aspiration. The median level of BALF α-amylase in cases was significantly higher than that in controls (2884.2 IU/L vs 30.0 IU/L, P < 0.001). The optimal cut-off was 179.1 IU/L (sensitivity 87.4%, specificity 93.3%, AUC 0.937, 95% CI 0.905-0.970). Subgroup analysis stratified by sex (male or female) and age (< 60 or ≥ 60 years) showed that the specificity and sensitivity remained above 0.80.
BALF α-amylase might be a promising biomarker for distinguishing aspiration syndrome.

PMID:
42602966
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.